Sculptor Capital LP Buys New Holdings in Sotera Health Company $SHC

Key Points

• Sculptor Capital acquired 24 million Sotera Health shares worth approximately $426 million, making SHC its third-largest holding and representing about 8.41% of the company. Institutional investors collectively own 91.03% of SHC.
• Analysts remain generally positive, with eight Buy ratings and three Holds, producing a consensus “Moderate Buy” rating and a $21.50 target price. Citigroup, Barclays, and Piper Sandler recently raised their price targets to $25, $22, and $25, respectively.
• Sotera Health exceeded quarterly expectations, reporting adjusted EPS of $0.26 versus a $0.24 consensus and revenue of $321.38 million, up 9.2% year over year. However, insiders sold roughly 1.29 million shares worth $24 million over the past 90 days.

Sculptor Capital LP purchased a new position in shares of Sotera Health Company (NASDAQ:SHC - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 24,000,000 shares of the company's stock, valued at approximately $426,000,000. Sotera Health accounts for 3.5% of Sculptor Capital LP's holdings, making the stock its 3rd biggest position. Sculptor Capital LP owned about 8.41% of Sotera Health at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Sotera Health during the second quarter worth approximately $428,635,000. Jupiter Topco LLC bought a new position in shares of Sotera Health in the 2nd quarter worth $149,137,000. Two Seas Capital LP acquired a new stake in Sotera Health in the 2nd quarter valued at $103,590,000. Lakewood Capital Management LP acquired a new stake in Sotera Health in the 2nd quarter valued at $70,638,000. Finally, Sachem Head Capital Management LP increased its stake in Sotera Health by 47.2% during the 4th quarter. Sachem Head Capital Management LP now owns 11,645,000 shares of the company's stock valued at $205,418,000 after purchasing an additional 3,735,000 shares in the last quarter. Institutional investors own 91.03% of the company's stock.

Analyst Ratings Changes

SHC has been the topic of several research reports. Weiss Ratings upgraded shares of Sotera Health from a "hold (c)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. UBS Group set a $19.00 price objective on shares of Sotera Health in a report on Wednesday, June 24th. Citigroup boosted their target price on shares of Sotera Health from $23.00 to $25.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Barclays upped their target price on shares of Sotera Health from $19.00 to $22.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Finally, Piper Sandler reiterated an "overweight" rating and set a $25.00 price target (up from $22.00) on shares of Sotera Health in a research note on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $21.50.

Insider Transactions at Sotera Health

In other Sotera Health news, insider Michael P. Rutz sold 150,000 shares of Sotera Health stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $18.84, for a total transaction of $2,826,000.00. Following the transaction, the insider owned 334,279 shares of the company's stock, valued at $6,297,816.36. This trade represents a 30.97% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of Sotera Health stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $18.50, for a total transaction of $15,725,000.00. Following the transaction, the chairman directly owned 3,969,393 shares in the company, valued at approximately $73,433,770.50. This represents a 17.64% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 1,294,515 shares of company stock valued at $23,999,528 over the last ninety days. 15.36% of the stock is currently owned by insiders.

Sotera Health Price Performance

SHC opened at $19.51 on Wednesday. The company has a debt-to-equity ratio of 3.33, a current ratio of 2.80 and a quick ratio of 2.55. The company has a market capitalization of $5.57 billion, a price-to-earnings ratio of 34.23 and a beta of 1.77. The firm's fifty day moving average price is $17.89 and its two-hundred day moving average price is $16.36. Sotera Health Company has a 1 year low of $13.09 and a 1 year high of $19.85.

Sotera Health (NASDAQ:SHC - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.02. The firm had revenue of $321.38 million during the quarter, compared to analyst estimates of $309.70 million. Sotera Health had a net margin of 13.44% and a return on equity of 40.12%. The business's revenue was up 9.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.20 EPS. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. As a group, analysts anticipate that Sotera Health Company will post 0.86 earnings per share for the current fiscal year.

About Sotera Health

Sotera Health Inc NASDAQ: SHC is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source